Riad Salem, Anne M. Noonan, Benjamin Spieler, Sarah B. White, Laura Kulik, Dex L. Underwood, Eric Heilbron, Binh Nguyen, Graham Wetherill, Renuka Iyer. "EMERALD-Y90: A phase 2 study to evaluate transarterial radioembolization (TARE) followed by durvalumab (D) and bevacizumab (B) for the treatment of participants (pts) with unresectable hepatocellular carcinoma (uHCC) eligible for embolization.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.tps4221